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1. Introduction 
α-Aminoisobutyric acid (Aib)1 and cyclic α,α-disubstituted α-
amino acid (Acnc)2 have been shown to stabilize the helical 
secondary structures of peptides and are widely used as helical 
inducers for peptide foldamers.  Aib and Acnc are achiral amino 
acids; and thus, their peptides have no helical-screw sense bias, 
both right-handedness (P) and left-handedness (M).  Many 
studies have attempted to regulate the helical-screw sense of Aib 
peptides by introducing chiral amino acids into the peptide 
sequence.3  Controlling the direction of the helical-screw sense is 
essential when designing peptide foldamers for biologically 
active molecules4 and asymmetric organocatalysts5.  We recently 
demonstrated that the chiral cyclic α,α-disubstituted α-amino acid 
bearing only side-chain chiral centers, (3R,4R)-1-amino-3,4-
diazido-1-cyclopentanecarboxylic acid [(R,R)-Ac5cdN3] controlled 
the right-handed (P) helical-screw sense of its homopeptide in the 
crystal state.6  A feature of Ac5cdN3 was that the azido groups in 
the side chain could be converted into various 1,2,3-triazole 
functional groups by the Huisgen 1,3-dipolar cycloaddition 
reaction (click reaction).  In the present study, we investigated 
whether the attachment of one, two, or three chiral amino acids 
bearing azido groups [(R,R)-Ac5cdN3] or 1,2,3-triazole functional  
groups [(R,R)-Ac5cd-triazole] was capable of controlling the helical-
screw sense of Aib peptides.  We have designed and synthesized 
Boc-(R,R)-Ac5cdN3-(Aib)4-OEt (1), Boc-(R,R)-Ac5cd-triazole-(Aib)4-
OEt (2), Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3), Boc-(Aib)2-
(R,R)-Ac5cd-triazole-(Aib)2-OEt (4), and Boc-[(R,R)-Ac5cdN3-
(Aib)2]n-OEt [n = 1 (5), n = 2 (6), n = 3 (7)], and determined their 












Fig. 1.  α,α-Disubstituted α-amino acids and their peptides in the present 
study. 
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The chiral cyclic α,α-disubstituted α-amino acid, (3R,4R)-1-amino-3,4-diazido-1-
cyclopentanecarboxylic acid [(R,R)-Ac5cdN3], was introduced into achiral α-aminoisobutyric acid 
(Aib) peptides.  The azido groups of (R,R)-Ac5cdN3 in the peptides were efficiently converted 
into 1,2,3-triazole functional groups.  FT-IR, 1H NMR, and CD spectra revealed that the 
dominant conformations of all peptides in solution were 310-helical structures without 
controlling the helical-screw sense.  X-ray crystallographic analyses of peptides containing 
(R,R)-Ac5cdN3 showed that both the right-handed (P) and left-handed (M) 310-helical structures 
were present in the crystal state. 
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2. Results 
2.1. Synthesis of amino acids and peptides 
The chiral five-membered ring amino acids Boc-(R,R)-
Ac5cdN3-OMe (8) and Boc-(R,R)-Ac5cd-triazole-OMe (9) were 
synthesized according to previously reported methods.6  The 
synthesis of peptides 1, 3, and 5–7 was achieved using fragment 
condensation solution-phase methods with O-benzotriazol-1-yl-
N,N,N’,N’-tetramethyluronium hexafluoro-phosphate (HBTU) or 
bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) as the 
coupling reagent (Scheme 1).7  The azido functional groups in 
peptides 1 and 3 were converted into triazole functional groups 
by a treatment with phenylacetylene in the presence of CuSO4 
and sodium ascorbate, and products 2 (quantitatively) and 4 


















Scheme 2.  Click conversion of the side-chain azido function of (R,R)-
Ac5cdN3. 
 
2.2. Conformational analysis in solution 
The dominant conformations of the peptides in CDCl3 
solution were initially examined using by FT-IR absorption 
spectroscopy.  Fig. 2 shows the IR absorption spectra of Boc-
(R,R)-Ac5cdN3-(Aib)4-OEt (1) and Boc-(R,R)-Ac5cd-triazole-(Aib)4-
OEt (2) (Fig. 2a), Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3) and 
Boc-(Aib)2-(R,R)-Ac5cd-triazole-(Aib)2-OEt (4) (Fig. 2b), and Boc-
[(R,R)-Ac5cdN3-(Aib)2]n-OEt [n = 1 (5), n = 2 (6), n = 3 (7)] (Fig. 
2c) in the 3250–3500 cm–1 region.  The weak bands in the 3420–
3440 cm–1 region were assigned to free (solvated) peptide NH 
groups, and the strong bands in the 3310–3370 cm–1 region were 
assigned to the intramolecularly hydrogen-bonded peptide NH 
groups.  The IR spectra of peptides 1–7 were very similar to 
those of the helical peptides in solution,1b,2b,3b,3c but differed 
markedly from those of peptides that formed the extended planar 
C5 conformation.8  The intensity of the band around the 3350 cm–
1 and 3335 cm–1 of (R,R)-Ac5cdN3 peptides 1 and 3, respectively, 
decreased after the click reaction in (R,R)-Ac5cd-triazole peptides 2 
and 4, which was consistent with the findings of a previous 
study.6  Furthermore, the low-frequency band observed at 3370 
cm–1 in tripeptide 5 shifted to a lower wavelength of 3310 cm–1 in 
nonapeptide 7, and its intensity steadily increased with the 
elongation of the peptide length.  These results were very similar 
to those for the Acnc homopeptides, which adopted a helical 




























Fig. 2.  FT-IR spectra (3250–3500 cm–1 region) of a) pentapeptides (R = 
azide: 1; R = triazole: 2), b) pentapeptides (R = azide: 3; R = triazole: 4), and 
c) Boc-[(R,R)-Ac5cdN3-(Aib)2]n-OEt (n = 1, 3 mer: 5; n = 2, 6 mer: 6; n = 3, 9 
mer: 7) in CDCl3 solution.  Peptide concentrations: 1 mM (a), 10 mM (b), and 











Fig. 3.  Plots of N–H chemical shifts in the 1H NMR spectra of the peptides a) Boc-(R,R)-Ac5cdN3-(Aib)4-OEt (1), b) Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3), c) 
Boc-(Aib)2-(R,R)-Ac5cd-triazole-(Aib)2-OEt (4), d) Boc-[(R,R)-Ac5cdN3-(Aib)2]2-OEt (6), and e) Boc-[(R,R)-Ac5cdN3-(Aib)2]3-OEt (7) as a function of an increase in 








Fig. 4.  Plots of the bandwidths of the N–H protons in the peptides a) Boc-(R,R)-Ac5cdN3-(Aib)4-OEt (1), b) Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3), c) Boc-
(Aib)2-(R,R)-Ac5cd-triazole-(Aib)2-OEt (4), d) Boc-[(R,R)-Ac5cdN3-(Aib)2]2-OEt (6), and e) Boc-[(R,R)-Ac5cdN3-(Aib)2]3-OEt (7) as a function of an increase in the 
percentage of TEMPO (w/v) added to the CDCl3 solution.  Peptide concentration: 1.0 mM. 
 
1H NMR experiments were performed for peptides 1, 3, 4, 6, 
and 7 in CDCl3 solution with the addition of dimethyl sulfoxide 
(DMSO; 0–10% (v/v)) (Fig. 3) or the free radical 2,2,6,6-
tetramethyl-1-piperidinyloxy (TEMPO; 0–0.05% (w/v)) (Fig. 4).  
Peptide 2 could not be analyzed because of the overlapping of 
several NH protons with the signals of triazole functional groups.  
Free NH groups without intramolecular hydrogen bonds were 
affected by the addition of DMSO or TEMPO.  In the 1H NMR 
spectra of peptides 1, 3, 4, 6, and 7, the N(1)H signals at the N-
terminus could be unambiguously determined by their high-field 
positions at δ = 5.39 ppm in 1, δ = 5.00 ppm in 3, δ = 5.03 ppm 
in 4, δ = 5.42 ppm in 6, and δ = 5.53 ppm in 7, due to their 
urethane structure, whereas the remaining four, five, or eight NH 
protons could not be assigned at this stage.  Two NH chemical 
shifts in peptides 1, 3, 4, 6, and 7 were sensitive to the addition 
of the perturbing reagent DMSO, and the bandwidths of two NH 
proton signals were broadened by the addition of the TEMPO 
radical.  These results demonstrated that the two NH protons 
were solvent-exposed, which suggested that they may not have 
been intramolecularly hydrogen-bonded.  Therefore, peptides 1, 
3, 4, 6, and 7 may have adopted a 310-helical structure, in which 
two NH groups [N(1)H and N(2)H] were free (solvated) of the 
intramolecular hydrogen bond. 
The nuclear Overhauser effect spectroscopy (NOESY) and/or 
rotating-frame nuclear Overhauser effect spectroscopy (ROESY) 
1H NMR spectra of peptides 1–4, 6, and 7 were measured in 
CDCl3 solution (Fig. 5).  The NOESY 1H NMR spectra of 
peptides 1–4 and 6 revealed a complete series of sequential NH 
(i→i+1) dipolar interactions, from the N-terminal N(1)H to the 
C-terminal N(5)H or N(6)H, respectively.  Sequential NH 
(i→i+1) dipolar interactions were used to identify the helical 
structures;9 however, these interactions alone did not enable an 
assessment of regarding whether a 310- or α-helical conformation 
was present.  The ROESY 1H NMR spectrum of nonapeptide 7 
showed a series of sequential NH (i→i+1) dipolar interactions 
from the N(3)H to the C-terminal N(9)H, respectively.  Although 
the interactions dNN (1→2) and dNN (2→3) are not shown, the 
series of sequential NOE cross peaks suggested the helical 
structure of 7.  In L-α-amino acid peptides and proteins, two 
NOE constraints, [dαN (i→i+2)] and [dαN (i→i+4)] were useful 
for the assignment of a 310- or α-helical structure.  No hydrogen 
at the α-carbon atom in the peptides 1–4, 6, and 7; thus, we could 
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Fig. 5.  The NOESY 1H NMR spectra of a) Boc-(R,R)-Ac5cdN3-(Aib)4-OEt 
(1), b) Boc-(R,R)-Ac5cd-triazole-(Aib)4-OEt (2), c) Boc-(Aib)2-(R,R)-Ac5cdN3-
(Aib)2-OEt (3), d) Boc-(Aib)2-(R,R)-Ac5cd-triazole-(Aib)2-OEt (4),  and e) Boc-
[(R,R)-Ac5cdN3-(Aib)2]2-OEt (6), and the ROESY 1H NMR spectrum of f) 
Boc-[(R,R)-Ac5cdN3-(Aib)2]3-OEt (7). 
The CD spectra of peptides 1–4, 6, and 7, and amino acids 8 
and 9 were measured in 2,2,2-trifluoroethanol solution to obtain 
information on the helical-screw sense of the peptides (Fig. S1 in 
the Supplementary Data).  However, the spectra of peptides 1–4, 
6, and 7 did not show the maximum characteristic of a helical 
structure (208 nm and 222 nm), which suggested the existence of 
roughly equivalent amounts of both right-handed (P) and left-
handed (M) helices.  The conversion of azido functional groups 
into triazole groups enhanced the intensity of the spectra (Figs. 
S1a and S1b); however, the chromophore of azido and triazole 
functional groups may have directly affected the CD spectra of 
their peptides (Figs. S1d and S1e). 
2.3. Conformational analysis in the crystal state 
Table 1.  Crystal and diffraction parameters of pentapeptide 3 and 
hexapeptide 6. 
 Pentapeptide 3 Hexapeptide 6 
Empirical formula C29H49N11O8 C35H46N18O9 
Mr 679.79 872.98 
Crystal diameters [mm] 0.50 × 0.25 × 0.20 0.40 × 0.30 × 0.25 
Crystal system monoclinic monoclinic 
Lattice parameters:   
  a, b, c [Å] 16.761, 11.651, 20.192 15.472, 17.458, 17.110 
  α, β, γ [˚] 90, 112.95, 90 90, 94.081, 90 
  V [Å3] 3631.0 4610.0 
Space group P21 P21 
Z value 4 4 
D calc [g/cm3] 1.244 1.258 
μ (MoKα) [cm–1] 0.93 0.94 
No. of observations 8386 [I > 2σ(I)] 9044 [I > 2σ(I)] 
No. of variables 884 1178 
R1, Rw 0.0387, 0.1030 0.0947, 0.2571 
Solvent MeOH/H2O MeOH/H2O 
 
Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3) and Boc-[(R,R)-
Ac5cdN3-(Aib)2]2-OEt (6) formed good crystals for X-ray 
crystallographic analysis due to slow evaporation of the solvent 
(MeOH/H2O) at room temperature.10  The crystal and diffraction 
parameters of 3 and 6 are summarized in Table 1.  The molecular 
structures of 3 and 6 are given in Figs. 6 and 7, respectively.  
Relevant backbone and side-chain torsion angles as well as intra- 
and intermolecular hydrogen-bond parameters are listed in 
Tables 2 and 3, respectively. 
Table 2.  Selected torsion angles ω, ϕ, and ψ [˚] for 3 and 6, as determined 
by X-ray crystallographic analysis. 
   Torsion Pentapeptide 3 Hexapeptide 6 
   Angle           A           B           C           D 
θ0 –171.4 175.6 –176.2 178.4 
ω0 –166.9 163.9 –170.0 171.8 
ϕ1 –57.6 58.2 –62.2 59.8 
ψ1 –38.8 40.6 –36.9 37.3 
ω1 –176.1 175.4 –172.3 171.9 
ϕ2 –51.8 52.7 –52.6 52.5 
ψ2 –36.0 35.3 –37.6 36.9 
ω2 –173.5 173.1 –176.1 176.4 
ϕ3 –59.9 59.9 –55.4 56.3 
ψ3 –28.1 28.0 –28.3 28.9 
ω3 –179.7 179.6 179.9 –179.3 
ϕ4 –57.7 59.5 –59.8 56.6 
ψ4 –38.0 36.2 –20.2 24.7 
ω4 –175.2 174.8 178.0 –179.0 
ϕ5 –55.0 55.0 –50.9 48.2 
ψ5 –49.0 45.8 –44.4 42.1 
ω5 178.8 –179.5 –175.9 166.4 
ϕ6 ––– ––– 28.7 –56.0 
ψ6 ––– ––– 63.7 153.1 
ω6 ––– ––– –166.3 171.1 
     
χ1 ––– ––– 130.4 101.8 
χ1 ––– ––– –103.7 –80.5 
χ3 138.1 149.0 ––– ––– 
χ3 –111.0 –122.7 ––– ––– 
χ4 ––– ––– 155.2 153.1 
χ4 ––– ––– –82.8 –127.2 
 
Table 3.  Intra- and intermolecular H-bond parameters for 3 and 6. 
Peptide Donor Acceptor Distance 
[Å] 





A (P) N3a-H O0a 2.95 150 x, y, z 
e) f) 
 5 
 N4a-H O1a 2.97 151 x, y, z 
 N5a-H O2a 3.07 144 x, y, z 
      
B (M) N3b-H O0b 2.95 149 x, y, z 
 N4b-H O1b 2.98 152 x, y, z 
 N5b-H O2b 3.05 145 x, y, z 
      
 N1a-H O4a’ 2.90 170 x, 1+y, z 
 N2a-H O5a’ 3.00 141 x, 1+y, z 
 N1b-H O4b’ 2.91 171 x, –1+y, z 
 N2b-H O5b’ 3.00 142 x, –1+y, z 
      
Boc-[(R,R)-Ac5cdN3-Aib-Aib]2-OEt (6) 
C (P) N3c-H O0c 3.37a 147 x, y, z 
 N4c-H O1c 2.88 155 x, y, z 
 N5c-H O2c 2.94 163 x, y, z 
 N6c-H O3c 3.10 145 x, y, z 
      
D (M) N3d-H O0d 3.27a 146 x, y, z 
 N4d-H O1d 2.87 150 x, y, z 
 N5d-H O2d 2.95 163 x, y, z 
 N6d-H O3d 3.12 163 x, y, z 
      
 N1c-H O4d’ 2.85 168 1–x, 0.5+y, 1–z 
 N2c-H O5d’ 2.99 124 1–x, 0.5+y, 1–z 
 N1d-H O4c’ 2.86 167 –x, 0.5+y, –z 
 N2d-H O5c’ 2.94 124 –x, 0.5+y, –z 
aThe D···A distance is a bit long for a hydrogen bond. 
Two crystallographically independent conformers A and B 
existed in the asymmetric unit of Boc-(Aib)2-(R,R)-Ac5cdN3-
(Aib)2-OEt (3) (Fig. 6).  One azido group in conformer B was 
disordered.  Conformer A was a right-handed (P) 310-helical 
structure while conformer B was a left-handed (M) 310-helical 
structure; thus, the relationship between the two conformers was 
diastereomeric (P) and (M) helices.  The average values of the 
torsion angles ϕ and ψ of amino acid residues (1–5) were –56.4˚, 
–38.0˚ in conformer A, and 57.1˚, 37.2˚ in conformer B.  The 
three consecutive intramolecular hydrogen bonds of i ← i+3 type 
(i = 0–2), that correspond to the 310-helical structure were detcted 
in each conformer.  Conformer A had three intramolecular 
hydrogen bonds between the H-N(3a) and C(0a)=O(0a) 
[N(3a)···O(0a) = 2.95 Å; N–H···O 150˚], the H-N(4a) and 
C(1a)=O(1a) [N(4a)···O(1a) = 2.97 Å; N–H···O 151˚], and the 
H-N(5a) and C(2a)=O(2a) [N(5a)···O(2a) = 3.07 Å; N–H···O 
144˚].  Conformer B shows three intramolecular hydrogen bonds 
between the H-N(3b) and C(0b)=O(0b) [N(3b)···O(0b) = 2.95 Å; 
N–H···O 149˚], the H-N(4b) and C(1b)=O(1b) [N(4b)···O(1b) = 
2.98 Å; N–H···O 152˚], and the H-N(5a) and C(2a)=O(2a) 
[N(5a)···O(2a) = 3.05 Å; N–H···O 145˚].  In the packing mode, 
conformer A was connected by intermolecular hydrogen bonds 
between the H-N(1a) and C(4a’)=O(4a’) [N(1a)···O(4a’) = 2.90 
Å; N–H···O 170˚] and the H-N(2a) and C(5a’)=O(5a’) 
[N(2a)···O(5a’) = 3.00 Å; N–H···O 141˚] of a symmetry-related 
molecule (x, 1+y, z), while conformer B was connected by 
intermolecular hydrogen bonds between the H-N(1b) and 
C(4b’)=O(4b’) [N(1b)···O(4b’) = 2.91 Å; N–H···O 171˚] and 
the H-N(2b) and C(5b’)=O(5b’) [N(2b)···O(5b’) = 3.00 Å; N–
H···O 142˚] of a symmetry-related molecule (x, –1+y, z), 
thereby forming a head-to-tail alignment of 310-helical chains, 











Fig. 6.  310-Helical secondary structures of Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-
OEt (3), determined by X-ray crystallographic analysis. 
The structure of Boc-[(R,R)-Ac5cdN3-(Aib)2]2-OEt (6) was 
solved in the space group P21.  Two crystallographically 
independent molecules C and D were found in the asymmetric 
unit.  A five-membered ring at residue 1 in conformer C was 
disordered by puckering.  Conformers C and D were folded into 
(P) and (M) 310-helical structures, respectively (Fig. 7).  The 
mean values of the torsion angles ϕ and ψ of the amino acid 
residues (1–5) were –56.2˚ and –33.5˚ in conformer C.  Reversal 
of the torsion angles occurred at the C-terminus residues, that is, 
the values of the ϕ and ψ torsion angles of Aib(6) were 28.7˚, 
63.7˚ in conformer C.  The average torsion angles ϕ and ψ of the 
amino acid residues (1–5) in conformer D (54.7˚ and 34.0˚) were 
closed to those for an ideal left-handed (M) 310-helical structure 
(60˚ and 30˚), while the values of the ϕ and ψ torsion angles of 
Aib(6) were –56.0˚, 153.1˚, which appeared to be a half extended 
conformation.  In conformers C and D, two hydrogen bonds of 
the i ← i+3 type were observed between the H-N(4c, d) and 
C(1c, d)=O(1c, d) [N(4c, d)···O(1c, d) = 2.88 Å (c), 2.87 Å (d); 
N–H···O 155˚ (c), 150˚ (d)], and the H-N(5c, d) and C(2c, 
d)=O(2c, d) [N(5c, d)···O(2c, d) = 2.94 Å (c), 2.95 Å (d); N–
H···O 163˚ (c), 163˚ (d)].  Furthermore, one weak hydrogen 
bond was observed between the H-N(6c, d) and C(3c, d)=O(3c, 
d) [N(6c, d)···O(3c, d) = 3.10 Å (c), 3.12 Å (d); N–H···O 145˚ 
(c), 163˚ (d)].  The distance between the H-N(3c, d) and C(0c, 
d)=O(0c, d) [N(3c, d)···O(0c, d) = 3.37 Å (c), 3.27 Å (d); N–
H···O 147˚ (c), 146˚ (d)] was a bit long for an intramolecular 
hydrogen bond.  In the packing mode, four intermolecular 
hydrogen bonds were observed between the H-N(1c) and 
C(4d’)=O(4d’) [N(1c)···O(4d’) = 2.85 Å; N–H···O 168˚] and the 
H-N(2c) and C(5d’)=O(5d’) [N(2c)···O(5d’) = 2.99 Å; N–H···O 
124˚] of a symmetry-related molecule (1–x, 0.5+y, 1–z), and the 
H-N(1d) and C(4c’)=O(4c’) [N(1d)···O(4c’) = 2.86 Å; N–H···O 
167˚] and between the H-N(2d) and C(5c’)=O(5c’) 
[N(2d)···O(5c’) = 2.94 Å; N–H···O 124˚] of a symmetry-related 
molecule (–x, 0.5+y, –z).  The 310-helical chains of C and D 
were packed to form a head-to-tail alignment of chain 
···A···B···A···B···A···B···. 
 












Fig. 7.  310-Helical secondary structures of Boc-[(R,R)-Ac5cdN3-(Aib)2]2-OEt 
(6), determined by X-ray crystallographic analysis. 
3. Discussion 
An optically active cyclic amino acid (R,R)-Ac5cdN3 having 
two azido functional groups was synthesized from L-tartaric 
acid.6  The synthesis of peptides 1, 3, and 5–7, which were 
composed of (R,R)-Ac5cdN3 and Aib, was achieved using the 
fragment condensation solution-phase method with HBTU or 
BOP-Cl as the coupling reagent with moderate yields (68–94%) 
(Scheme 1).  In the click reaction of the azido groups in peptides 
1 and 3 with phenylacetylene, the isolated products were 
di(1,2,3-triazole) products with excellent yields (99–100%) 
(Scheme 2), but not mono(1,2,3-triazole) products, which is 
consistent with the findings of a previous study.6 
The preferred conformation of peptides 1–7 was determined 
in solution.  The FT-IR spectra of the peptides were very similar 
to those of the Aib and Acnc peptides,1b,2b which indicated the 
existence of helices (Fig. 2).  The NOESY (ROESY) 1H NMR 
spectra of the peptides showed a complete (peptides 1–4 and 6) 
or partial (peptide 7) series of sequential NH dipolar interactions 
[dNN (i → i+1)] from the N-terminal NH to the C-terminal NH, 
which suggested the formation of helical structures (Fig. 5).  The 
1H NMR measurements obtained for peptides 1, 3, 4, 6, and 7 in 
the presence of DMSO (Fig. 3) or the TEMPO radical (Fig. 4) 
suggested the existence of 310-helical conformations in solution 
because two NH proton signals were affected by both additives.  
However, the CD spectra of peptides 1–4, 6, and 7 did not show 
characteristic maxima for a helical structure (Fig. S1).  The 
chromophore of the azido and triazole functional groups 
appeared to directly affect the CD spectra (Figs. S1d and S1e).  
Taken together, all the peptides formed 310-helical structures in 
solution without controlling their helical-screw sense.  These 
results were consistent with the findings of previous studies, in 
which one chiral α,α-disubstituted α-amino acid could not 
control the 310-helical-screw sense of the Aib tetrapeptides.3b,3c,3e  
Although peptides 6 and 7 possessed two and three (R,R)-Ac5cdN3 
in four and six Aib residues, respectively, they did not 
immobilize the helical structures in one direction.  More (R,R)-
Ac5cdN3 or (R,R)-Ac5cd-triazole amino acids should be introduced to 
control the helical-screw sense of Aib peptides.  Furthermore, 
conversion of the azido groups of peptides into triazole groups 
did not cause a marked conformational change.  A bulkier 
substituent than the phenyl group may have affected the 
secondary strucutre.  X-ray crystallographic analyses revealed 
that the conformations of pentapeptide 3 and hexapeptide 6 were 
both right-handed (P) and left-handed (M) 310-helical structures 
in the crystal state.  The helical-screw sense of the peptides 
designed in this study was not controllable not only in solution, 
but also in the crystal state. 
4. Conclusion 
The chiral cyclic α,α-disubstituted α-amino acids (R,R)-
Ac5cdN3 and (R,R)-Ac5cd-triazole with azido and triazole functional 
groups in the side chain, respectively, were introduced into Aib 
peptides.  The dominant conformations of the peptides in 
solution were found to be 310-helical structures by FT-IR, 1H 
NMR, and 2D NOESY and/or ROESY spectra.  Furthermore, the 
CD spectra suggested the existence of roughly equivalent 
amounts of both right-handed (P) and left-handed (M) helices.  
The preferred conformations of peptides 3 and 6 were studied by 
X-ray crystallographic analyses, and the results obtained 
indicated the existence of both right-handed (P) and left-handed 
(M) 310-helices in the crystal state.  The side-chain chiral centers 
in (R,R)-Ac5cdN3 and (R,R)-Ac5cd-triazole could not control the 
helical-screw sense to one-handedness in these Aib-based 
peptides. 
5. Experimental section 
5.1. General 
(3R,4R)-3,4-Diazido-1-(tert-
butoxycarbonylamino)cyclopentanecarboxylic acid methyl ester 
[Boc-(R,R)-Ac5cdN3-OMe: 8], Boc-(R,R)-Ac5cd-triazole-OMe (9), 
Boc-(R,R)-Ac5cdN3-OH, H-(Aib)4-OEt, H-(Aib)2-OEt, and Boc-
(Aib)2-OH were prepared according to the previously reported 
methods.[1,2]  Optical rotations [α]rtD were measured with a Jasco 
DIP-316 polarimeter using a 0.5 or 1.0 dm cell.  Circular 
dichroism (CD) spectra were measured with a Jasco J-720W 
spectropolarimeter using a 1.0 mm path length cell.  Infrared 
(IR) spectra were recorded on a Nicolet Avatar-320 spectrometer, 
Shimazu IRAffinity-1, or Jasco FT/IR-420 spectrometer for 
conventional measurement (KBr), and the solution (CDCl3) 
method using 0.1 mm path length of NaCl cell.  1H NMR spectra 
were determined at 400 or 500 MHz (Varian Unity).  FAB-MS 
spectra were taken on a Jeol JMS-D300 or Jeol JMS-SX 102 
spectrometer. 
5.2. Synthesis of peptides 
5.2.1.  Boc-(R,R)-Ac5cdN3-(Aib)4-OEt (1).  A solution of acid Boc-
(R,R)-Ac5cdN3-OH (125 mg, 0.40 mmol), amine H-(Aib)4-OEt 
(147 mg, 0.38 mmol), O-benzotriazol-1-yl-N,N,N’,N’-
tetramethyluronium hexafluoro-phosphate (HBTU, 151 mg, 0.40 
mmol), and iPr2EtN (130 µL, 0.76 mmol) in MeCN (2 mL) was 
stirred at 40˚C for 4 days.  After evaporation of the solvent, the 
residue was diluted with CH2Cl2, washed with saturated aqueous 
NaHCO3, brine, and dried over MgSO4.  Removal of the solvent 
afforded a residue, which was purified by column 
chromatography on silica gel.  The fraction eluted with 10% 
MeOH in CHCl3 gave pentapeptide 1 (177 mg, 68%) as colorless 
crystals: m.p. 243˚C (decomp.); [α]D23 = –13.2 (c 1.00, CHCl3); 
IR (CDCl3) ν 3348, 2985, 2360, 2111, 1730, 1676, 1527, 1256 
cm–1; 1H NMR (400 MHz, CDCl3) δ 7.42 (br s, 1H), 7.37 (br s, 
1H), 7.14 (br s, 1H), 6.62 (br s, 1H), 5.54 (br s, 1H), 4.14 (q, J = 
6.8 Hz, 2H), 3.98—3.99 (m, 2H), 2.79 (m, 1H), 2.51 (m, 1H), 
2.28 (m, 1H), 1.80 (m, 1H), 1.55 (s, 4H), 1.52 (s, 10H), 1.46—
1.48 (m, 15H), 1.44 (s, 4H), 1.25 (t, J = 6.8 Hz, 3H); 
FAB(+)HRMS calcd for C29H50N11O8 [M+ + H]: 680.3844; 
found: 680.3812. 
5.2.2.  Boc-(R,R)-Ac5cdN3-(Aib)2-OEt (5).  A solution of acid Boc-
(R,R)-Ac5cdN3-OH (196 mg, 0.63 mmol), amine H-(Aib)2-OEt 
(136 mg, 0.63 mmol), HBTU (239 mg, 0.63 mmol), and iPr2EtN 
(220 µL, 1.26 mmol) in MeCN (10 mL) was stirred at 40˚C for 2 
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days.  After evaporation of the solvent, the residue was diluted 
with EtOAc, washed with saturated aqueous NaHCO3, brine, and 
dried over MgSO4.  Removal of the solvent afforded a residue, 
which was purified by column chromatography on silica gel.  
The fraction eluted with 30% EtOAc in n-hexane gave tripeptide 
5 (218 mg, 68%) as colorless crystals: m.p. 158—160˚C; [α]D23 = 
–15.8 (c 1.05, CHCl3); IR (CDCl3) ν 3293, 2983, 2106, 1727, 
1694, 1660, 1530, 1254, 1172 cm–1; 1H NMR (400 MHz, CDCl3) 
δ 7.07 (br s, 1H), 6.62 (br s, 1H), 5.07 (br s, 1H), 4.13 (q, J = 7.2 
Hz, 2H), 3.93 (m, 1H), 3.85 (m, 1H), 2.77 (m, 1H), 2.44 (m, 1H), 
2.20 (m, 1H), 1.71 (m, 1H), 1.49 (s, 7H), 1.45—1.47 (m, 14H), 
1.19 (t, J = 7.4 Hz, 3H); FAB(+)HRMS calcd for C21H36N9O6 
[M+ + H]: 510.2789; found: 510.2792. 
5.2.3.  Boc-(R,R)-Ac5cdN3-(Aib)2-OH.  A solution of tripeptide 5 
(47 mg, 0.098 mmol) in MeOH (3 mL) and 0.1 M aqueous 
NaOH (8.9 mL, 0.89 mmol) was stirred at room temperature for 
24 h.  After acidification with 1M aqueous HCl, MeOH was 
evaporated.  The aqueous solution was then extracted with 
EtOAc, and dried over Na2SO4.  Removal of the solvent 
produced a crude carboxylic acid Boc-(R,R)-Ac5cdN3-(Aib)2-OH 
(47 mg, quant), which was used for next reaction without 
purification: 1H NMR (400 MHz, CD3OD) δ 7.87 (br s, 1H), 
7.57 (br s, 1H), 3.81—3.95 (m, 2H), 2.84 (m, 1H), 2.25 (m, 1H), 
2.12 (m, 1H), 1.75 (m, 1H), 1.47 (s, 21H). 
5.2.4.  H-(R,R)-Ac5cdN3-(Aib)2-OEt.  A mixture of tripeptide 5 
(218 mg, 0.43 mmol) in concentrated aqueous HCl (3 mL) and 
EtOAc (10 mL) was stirred at room temperature for 12 h.  The 
solution was alkalized with saturated aqueous NaHCO3, 
extracted with EtOAc, dried over MgSO4.  Removal of the 
solvent produced a crude amine H-(R,R)-Ac5cdN3-(Aib)2-OEt 
(176 mg, quant), which was used for next reaction without 
purification: 1H NMR (400 MHz, CDCl3) δ 8.09 (br s, 1H), 7.29 
(br s, 1H), 4.19 (q, J = 7.2 Hz, 2H), 4.03 (m, 1H), 3.95 (m, 1H), 
2.73 (m, 1H), 2.43 (m, 1H), 2.03 (m, 1H), 1.76 (br s, 1H), 1.55 (s, 
12H), 1.26 (t, J = 7.2 Hz, 3H). 
5.2.5.  Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3).  A solution of 
acid Boc-(Aib)2-OH (62 mg, 0.215 mmol), amine H-(R,R)-
Ac5cdN3-(Aib)2-OEt (73 mg, 0.18 mmol), bis(2-oxo-3-
oxazolidinyl)phosphinic chloride (BOP-Cl, 55 mg, 0.215 mmol), 
and iPr2EtN (63 µL, 0.36 mmol) in CH2Cl2 (3 mL) was stirred at 
30˚C for 7 days.  After evaporation of the solvent, the residue 
was diluted with CH2Cl2, washed with saturated aqueous 
NaHCO3, brine, and dried over MgSO4.  Removal of the solvent 
afforded a residue, which was purified by column 
chromatography on silica gel.  The fraction eluted with 25% 
EtOAc in n-hexane gave pentapeptide 3 (63 mg, 72% based on 
recovered material) as colorless crystals: m.p. 211—213˚C; 
[α]D23 = +12.0 (c 1.05, CHCl3); IR (CDCl3) ν 3291, 2986, 2111, 
1731, 1681, 1652, 1538, 1300, 1169 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 8.09 (br s, 1H), 7.52 (br s, 1H), 7.09 (br s, 1H), 6.65 
(br s, 1H), 5.50 (br s, 1H), 4.14 (q, J = 6.4 Hz, 2H), 3.92 (m, 1H), 
3.79 (m, 1H), 3.13 (m, 1H), 2.53 (m, 1H), 2.17 (m, 1H), 1.85 (m, 
1H), 1.53 (s, 6H), 1.51 (s, 11H), 1.48 (s, 2H), 1.43 (s, 4H), 1.23 
(t, J = 7.2 Hz, 3H); FAB(+)HRMS calcd for C29H50N11O8 [M+ + 
H]: 680.3844; found: 680.3834. 
5.2.6.  Boc-[(R,R)-Ac5cdN3-(Aib)2]2-OEt (6).  A solution of crude 
acid Boc-(R,R)-Ac5cdN3-(Aib)2-OH (239 mg, 0.496 mmol), crude 
amine H-(R,R)-Ac5cdN3-(Aib)2-OEt (234 mg, 0.48 mmol), BOP-
Cl (126 mg, 0.496 mmol), and iPr2EtN (173 µL, 0.992 mmol) in 
ClCH2CH2Cl (8 mL) was stirred at 45˚C for 17 days.  After 
evaporation of the solvent, the residue was diluted with CH2Cl2, 
washed with saturated aqueous NaHCO3, brine, and dried over 
MgSO4.  Removal of the solvent afforded a residue, which was 
purified by column chromatography on silica gel.  The fraction 
eluted with 10% MeOH in CHCl3 gave hexapeptide 6 (406 mg, 
94%) as colorless crystals: m.p. 221˚C (decomp.); [α]D27 = +7.25 
(c 1.11, CHCl3); IR (CDCl3) ν 3406, 3326, 2987, 2938, 2111, 
1670, 1528, 1256, 1156 cm–1; 1H NMR (400 MHz, CDCl3) δ 
7.86 (br s, 1H), 7.55 (br s, 1H), 7.46 (br s, 1H), 7.16 (br s, 1H), 
6.85 (br s, 1H), 5.85 (br s, 1H), 4.14 (q, J = 6.4 Hz, 2H), 3.99—
4.04 (m, 2H), 3.95 (m, 1H), 3.87 (m, 1H), 3.06 (br s, 1H), 2.92 
(br s, 1H), 2.58 (m, 1H), 2.26—2.35 (m, 3H), 1.99 (m, 1H), 1.90 
(m, 1H), 1.45—1.56 (m, 33H), 1.24 (t, J = 7.1 Hz, 3H); 
FAB(+)HRMS calcd for C35H57N18O9 [M+ + H]: 873.4556; 
found: 873.4551. 
5.2.7.  H-[(R,R)-Ac5cdN3-(Aib)2]2-OEt.  A mixture of hexapeptide 
6 (75 mg, 0.086 mmol) in concentrated aqueous HCl (1 mL) and 
EtOAc (3 mL) was stirred at room temperature for 12 h.  The 
solution was alkalized with saturated aqueous NaHCO3, 
extracted with EtOAc, dried over MgSO4.  Removal of the 
solvent produced a crude amine H-[(R,R)-Ac5cdN3-(Aib)2]2-OEt 
(59 mg, 78%), which was used for next reaction without 
purification: 1H NMR (400 MHz, CDCl3) δ 8.29 (br s, 1H), 7.99 
(br s, 1H), 7.44 (br s, 1H), 7.14 (br s, 1H), 6.33 (br s, 1H), 
4.09—4.14 (m, 2H), 3.87—3.95 (m, 2H), 2.96 (br s, 1H), 2.55—
2.63 (m, 2H), 2.29—2.34 (m, 2H), 2.04—2.09 (m, 2H), 1.83 (br 
s, 2H), 1.70 (m, 1H), 1.50 (s, 24H), 1.43 (s, 3H), 1.26 (t, J = 7.2 
Hz, 3H). 
5.2.8.  Boc-[(R,R)-Ac5cdN3-(Aib)2]3-OEt (7).  A solution of crude 
acid Boc-(R,R)-Ac5cdN3-(Aib)2-OH (76 mg, 0.157 mmol), crude 
amine H-[(R,R)-Ac5cdN3-(Aib)2]2-OEt (94 mg, 0.122 mmol), 
BOP-Cl (40 mg, 0.157 mmol), and iPr2EtN (43 µL, 0.244 mmol) 
in ClCH2CH2Cl (3 mL) was stirred at 45˚C for 19 days.  After 
evaporation of the solvent, the residue was diluted with CH2Cl2, 
washed with saturated aqueous NaHCO3, brine, and dried over 
MgSO4.  Removal of the solvent afforded a residue, which was 
purified by column chromatography on silica gel.  The fraction 
eluted with 10% MeOH in CHCl3 gave nonapeptide 7 (43 mg, 
74% based on recovered material) as colorless crystals: m.p. 
238˚C (decomp.); [α]D27 = +25.0 (c 0.89, CHCl3); IR (CDCl3) ν 
3308, 2982, 2933, 2357, 2110, 1661, 1533, 1255, 1169 cm–1; 1H 
NMR (400 MHz, CDCl3) δ 7.98 (br s, 1H), 7.94 (br s, 1H), 7.86 
(br s, 1H), 7.65 (br s, 1H), 7.52 (br s, 1H), 7.41 (br s, 1H), 7.15 
(br s, 1H), 6.81 (br s, 1H), 5.53 (br s, 1H), 4.14 (q, J = 6.9 Hz, 
2H), 4.00 (m, 4H), 3.92 (m, 2H), 3.12—3.65 (m, 4H), 2.68 (m, 
2H), 2.67—2.69 (m, 2H), 2.25—2.27 (m, 2H), 1.84—2.17 (m, 
4H), 1.45—1.54 (m, 45H), 1.22—1.24 (m, 3H); FAB(+)HRMS 
calcd for C49H78N27O12 [M+ + H]: 1236.6323; found: 1236.6295. 
5.2.9.  Boc-(R,R)-Ac5cd-triasole-(Aib)4-OEt (2).  A mixture of Boc-
(R,R)-Ac5cdN3-(Aib)4-OEt (1) (50 mg, 0.074 mmol), 
phenylacetylene (19.5 µL, 0.18 mmol), sodium ascorbate (7 mg, 
0.037 mmol), and CuSO4 (6 mg, 0.037 mmol) in t-BuOH (2 mL) 
and H2O (1 mL) was stirred at room temperature for 4 days.  
After evaporation of the solvent, the residue was diluted with 
H2O, extracted with CH2Cl2, and dried over MgSO4.  Removal of 
the solvent afforded a residue, which was purified by column 
chromatography on silica gel.  The fraction eluted with 10% 
MeOH in CHCl3 gave peptide 2 (42 mg, quant) as colorless 
crystals: m.p. 228—230˚C; [α]D23 = –43.5 (c 1.00, CHCl3); IR 
(CDCl3) ν 3349, 2986, 2361, 1730, 1677, 1525 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 7.93 (br s, 1H), 7.87 (br s, 1H), 7.79—7.83 
(m, 4H), 7.56 (br s, 1H), 7.41—7.45 (m, 5H), 7.35—7.38 (m, 
3H), 7.14 (br s, 1H), 6.79 (br s, 1H), 5.79 (m, 1H), 5.43 (m, 1H), 
4.14 (q, J = 7.2 Hz, 2H), 3.27 (m, 1H), 3.14 (m, 1H), 3.03 (m, 
1H), 2.77 (m, 1H), 1.54 (s, 12H), 1.53 (s, 9H), 1.51 (s, 6H), 1.48 
(s, 3H), 1.24 (t, J = 7.2 Hz, 3H); FAB (+)HRMS calcd for 
C45H62N11O8 [M+ + H]: 884.4783; found: 884.4812. 
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5.2.10.  Boc-(Aib)2-(R,R)-Ac5cd-triasole-(Aib)2-OEt (4).  A mixture 
of Boc-(Aib)2-(R,R)-Ac5cdN3-(Aib)2-OEt (3) (48 mg, 0.071 
mmol), phenylacetylene (37.2 µL, 0.34 mmol), sodium ascorbate 
(14 mg, 0.072 mmol), and CuSO4 (11 mg, 0.072 mmol) in t-
BuOH (2 mL) and H2O (1 mL) was stirred at room temperature 
for 7 days.  After evaporation of the solvent, the residue was 
diluted with H2O, extracted with CH2Cl2, and dried over MgSO4.  
Removal of the solvent afforded a residue, which was purified 
by column chromatography on silica gel.  The fraction eluted 
with 10% MeOH in CHCl3 gave peptide 4 (62 mg, 99%) as 
colorless crystals: m.p. 145—147˚C; [α]D23 = –49.1 (c 0.86, 
CHCl3); IR (CDCl3) ν 3299, 2986, 2937, 2351, 1731, 1681, 1538, 
1165 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.46 (br s, 1H), 8.12 
(br s, 1H), 7.79 (d, J = 7.7 Hz, 2H), 7.73 (d, J = 7.1 Hz, 2H), 
7.72 (br s, 1H), 7.65 (br s, 1H), 7.37—7.42 (m, 4H), 7.29—7.33 
(m, 2H), 7.10 (br s, 1H), 6.66 (br s, 1H), 5.78 (m, 1H), 5.48 (m, 
1H), 5.05 (s, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.96 (m, 1H), 3.43 
(br s, 1H), 3.18 (m, 1H), 2.84 (m, 1H), 1.46—1.59 (m, 33H), 
1.24 (t, J = 7.1 Hz, 3H); FAB (+)HRMS calcd for C45H62N11O8 
[M+ + H]: 884.4783; found: 884.4764. 
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